

The Centers for Medicare and Medicaid Services (CMS) is jointly sponsoring with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) two clinical trials to evaluate the effectiveness of more frequent hemodialysis sessions compared with conventional thrice-weekly hemodialysis. One of these trials compares daily in-center hemodialysis (6 times per week) with conventional in-center hemodialysis (3-times per week). The other compares nocturnal hemodialysis (6 times per week in the home) with conventional in-center hemodialysis. CMS has agreed to pay for covered patient care-related expenses for Medicare beneficiaries enrolled in these trials. For patients enrolled in the experimental arms of these trials (more frequent in-center or nocturnal hemodialysis), CMS also authorizes payment for one additional composite for the duration of the trial. The duration of the daily in-center hemodialysis trial will be 12 months after patient enrollment. The duration of the nocturnal hemodialysis trial will be 14 months after patient enrollment. For patients enrolled in the experimental arm of the nocturnal hemodialysis trial, CMS also authorizes additional home dialysis training payment at the composite payment rate plus \$20 for each training session incurred not to exceed 30 training session payments per patient. The standard Medicare deductibles and co-payments will apply to both composite rate payments and training session payments.

For more information about how Medicare will provide payment for additional services under these trials go to: (See CMS Related Links Inside below: R145OTN)

List of Participating Centers: (See downloads area below for more information: list of facilities)

For more information, (See CMS Related Links Outside below: NIDD)